Metformin associated lactic acidosis in a renal transplant patient

Böbrek nakil hastasında metforminle ilişkili laktik asidoz

Mehmet Gökhan Gök1, Saime Paydaş1, Engin Onan1, Erkan Demir1

1Cukurova University School of Medicine Department of Internal Medicine Nephrology, Adana. Turkey

Abstract

Although metformin is a well tolerated anti-hyperglycemic drug it may cause lactic acidosis which has high mortality. In this paper we reported a renal transplant patient with lactic acidosis. Fifty-five year old renal transplant patient was admitted to our hospital with confusion and lactic acidosis. Her confusion improved dramatically after restoring blood glucose, supportive therapy and hemodialysis. Her obstructive ureteral stone was removed with ureteral catheterization. In follow up period her renal function was similar to baseline. In summary rapid diagnosis and also appropriate treatment including hemodialysis can prevent morbidity/mortality in a patient with metformin associated lactic acidosis. Metformin users, especially renal transplant receivers who have high risk of acute renal failure, should be educated about the discontinuation of the drug when their urine volume decreased.

Key words: Metformin, lactic acidosis, renal transplant receiver, hemodialysis

INTRODUCTION

Metformin is a first-class oral anti-hyperglycemic agent used for treatment of type2 diabetes mellitus (T2DM). The most common side effects of metformin are diarrhea, nausea and vomiting. Lactic acidosis is a rare but serious side effect of this drug1. Here we presented uremia and severe lactic acidosis and acute renal failure secondary to ureterolithiasis associated with metformin using in a case with renal transplant receiver.

CASE

55 year-old-woman admitted to intensive care unit (ICU) with confusion. She had been transplanted 7 years ago. She had the history of nausea, vomiting and decreased urine output in the last three days. On physical exam Glasgow Coma Scale was 9-10. Blood pressure was 140/80 mmHg, pulse 92 was per minute, temperature was 37⁰C. There were crepitant rales at lungs and moderate pretilial edema. She had been treated with tacrolimus, mycophenolate mofetil, prednisolone, metformin and glimepiride for the last 7 years. She had been operated for lumbal disc hernia at another center two weeks ago. Her renal function tests were normal and blood glucose, HbA1c and serum tacrolimus levels were within targeted limits. Laboratory tests in the last 30 days and during
clinical follow up in the last 5 days were summarized on Table 1. Blood glucose was found as 17mg/dl in ICU. Blood glucose returned to normal level after dextrose infusion but her confusion did not improve. Abdominal ultrasound showed slightly enlarged transplanted kidney, dilatation at renal pelvis (2 cm) and grade 2 hydronephrosis. Her condition dramatically improved following immediate hemodialysis. Following 6 hours of hemodialysis, confusion and lactic acidosis improved. Ureretal calculi causing hydrenephrosis was removed by catheter. After catheretization oliguria and uremia disappeared. Her blood sugar was regulated with insulin. The maintenance immunosuppressive medications were re-started. In follow up period any adverse event did not develop.

Table 1. Laboratory findings during hospitalization and pre-post hospital period

<table>
<thead>
<tr>
<th></th>
<th>BUN</th>
<th>Creatinine</th>
<th>Glucose</th>
<th>Na</th>
<th>K</th>
<th>Ca</th>
<th>pH</th>
<th>HCO3</th>
<th>pCO2</th>
</tr>
</thead>
<tbody>
<tr>
<td>30th day</td>
<td>13</td>
<td>0.61</td>
<td>115</td>
<td>138</td>
<td>9.9</td>
<td>4</td>
<td>9.9</td>
<td>10.6</td>
<td>26.6</td>
</tr>
<tr>
<td>Admission</td>
<td>105</td>
<td>7.95</td>
<td>17</td>
<td>134</td>
<td>5.96</td>
<td>8.62</td>
<td>7.15</td>
<td>16.8</td>
<td>27.9</td>
</tr>
<tr>
<td>Day 1</td>
<td>30</td>
<td>5.59</td>
<td>129</td>
<td>125</td>
<td>4.5</td>
<td>8.1</td>
<td>7.39</td>
<td>19.3</td>
<td>35.6</td>
</tr>
<tr>
<td>Day 2</td>
<td>36</td>
<td>5.3</td>
<td>124</td>
<td>119</td>
<td>3.6</td>
<td>7.9</td>
<td>7.37</td>
<td>19.3</td>
<td>35.6</td>
</tr>
<tr>
<td>Day 3</td>
<td>47</td>
<td>3.55</td>
<td>125</td>
<td>131</td>
<td>3.1</td>
<td>8.3</td>
<td>7.40</td>
<td>25.4</td>
<td>41.8</td>
</tr>
<tr>
<td>Day 4</td>
<td>45</td>
<td>1.79</td>
<td>126</td>
<td>140</td>
<td>3</td>
<td>8.7</td>
<td>7.38</td>
<td>25.5</td>
<td>43.7</td>
</tr>
<tr>
<td>Day 5</td>
<td>28</td>
<td>1.11</td>
<td>123</td>
<td>134</td>
<td>3.4</td>
<td>8.2</td>
<td>7.34</td>
<td>22.3</td>
<td>42</td>
</tr>
<tr>
<td>Day 6</td>
<td>16</td>
<td>0.91</td>
<td>117</td>
<td>139</td>
<td>3.9</td>
<td>8.1</td>
<td>7.37</td>
<td>23.3</td>
<td>41.2</td>
</tr>
</tbody>
</table>

DISCUSSION

Metformin improves hyperglycemia by reducing hepatic gluconeogenesis and stimulating intracellular glucose uptake. Major routes of metformin elimination are glomerular filtration and tubular secretion. Metformin related adverse events may develop due to decreased clearance and metformin dosage must be reduced in patients with decreased glomerular filtration rate (GFR) (<30-45 ml/minute).

The most serious side effect of metformin use is lactic acidosis. This side effect is more common in patients with co-morbid diseases such as renal failure and liver dysfunction. Lactate is substrate for hepatic gluconeogenesis and can be eliminated from kidneys. For this reason blood lactate level does not increase significantly in healthy people. However in the presence of renal dysfunction lactate and metformin clearance decrease and their blood levels increase. Clinically significant lactic acid accumulation occurs in cases with renal insufficiency (serum creatinine > 1.4 mg/dL [124 μmol/L] in women and 1.5 mg/dL [132 μmol/L] in men), or low creatinine clearance, and also in cases with concurrent liver disease, alcohol abuse, heart failure, history of lactic acidosis, decreased tissue perfusion or hemodynamic instability, hypoxic states or severe acute illness. In our case, predisposing factor was acute renal failure due to ureteral calculus in transplanted kidney.

Metformin-associated lactic acidosis (MALA) is defined as a syndrome of high blood lactate level with acidemia in patients treated with metformin, after excluding other causes of lactic acidosis. It can also develop in cases receiving toxic doses of metformin and even in therapeutic doses. The incidence of MALA is not clearly documented with estimated 3 and 9 cases per 100,000 patient year. However its mortality is extremely high, more than half of the patients die. Mortality and morbidity decrease with the early hemodialysis. The treatment involves correction of acidosis and also to remove the causes of lactic acidosis and supportive therapy. Hemodialysis relieves lactic acidosis and also efficiently removes metformin and lactate from plasma and prevents further lactate accumulation. Following 6 hours of hemodialysis, impairment of consciousness and lactic acidosis improved in our patient. Confusion and lactic acidosis recovered after glucose infusion and hemodialysis. Previously we successfully treated a hemodialysis patient with coma and Metformin induced lactic acidosis.

In conclusion, lactic acidosis and hypoglycemia due to metformin using in a renal transplant case, dramatically improved with hemodialysis and supportive care. After removing the obstruction, function of transplanted kidney regained to baseline.
levels at follow-up period. Therefore we must be careful in the use of metformin in cases with renal transplantation who are high risk for acute kidney injury including obstructive renal disease. Metformin users especially renal transplant patients who have high risk of acute renal failure, should be educated about the discontinuation of the drug when their urine volume decreased.

REFERENCES